CAMP Camp4 Therapeutics Corp

Nasdaq www.camp4tx.com


$ 3.70 $ 0.24 (6.9 %)    

Friday, 24-Oct-2025 19:09:47 EDT
QQQ $ 617.50 $ 6.52 (1.07 %)
DIA $ 472.45 $ 4.92 (1.05 %)
SPY $ 677.25 $ 5.49 (0.82 %)
TLT $ 91.47 $ 0.04 (0.04 %)
GLD $ 378.59 $ -1.27 (-0.34 %)
$ 3.72
$ 3.55
$ 3.00 x 200
$ 3.72 x 400
$ 3.52 - $ 3.72
$ 1.31 - $ 12.26
66,289
na
74.99M
$ 1.69
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-27-2025 12-31-2024 10-K
4 11-21-2024 09-30-2024 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 cantor-fitzgerald-initiates-coverage-on-camp4-therapeutics-with-overweight-rating-announces-price-target-of-7

Cantor Fitzgerald analyst Steve Seedhouse initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight rating an...

 jp-morgan-downgrades-camp4-therapeutics-to-neutral

JP Morgan analyst Anupam Rama downgrades Camp4 Therapeutics (NASDAQ:CAMP) from Overweight to Neutral.

 piper-sandler-maintains-overweight-on-camp4-therapeutics-lowers-price-target-to-12

Piper Sandler analyst Edward Tenthoff maintains Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and lowers the price targ...

 camp4-therapeutics-secures-50m-initial-financing-with-potential-for-additional-50m-to-fund-syngap1-phase-12-clinical-trial

Oversubscribed Financing led by Coastlands Capital with participation from new and existing investorsFinancing to provide $50 m...

 wedbush-initiates-coverage-on-camp4-therapeutics-with-outperform-rating-announces-price-target-of-8

Wedbush analyst Yun Zhong initiates coverage on Camp4 Therapeutics (NASDAQ:CAMP) with a Outperform rating and announces Pric...

 camp4-unveils-syngap1-and-urea-cycle-disorder-data-at-asgct-2024-highlighting-protein-boost-and-safety-progress

CAMP4 Therapeutics Corporation, a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting th...

 camp4-therapeutics-q1-eps-062-up-from-2657-yoy-sales-85800k

Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.62) per share. This is a 97.67 percent increase over losses o...

 camp4-announces-it-will-present-new-preclinical-data-from-its-urea-cycle-disorders-and-syngap1-related-disorders-programs-at-28th-american-society-of-gene-and-cell-therapy-annual-meeting-may13-17-2025-in-new-orleans-lousiana

Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upr...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION